Cell Therapy Raw Materials Market To Reach $21.88 Billion By 2033

Cell Therapy Raw Materials Market Growth & Trends

The global Cell Therapy Raw Materials market size is expected to reach USD 21.88 billion by 2033, registering a CAGR of 19.15% from 2026 to 2033, according to a new report by Grand View Research, Inc. The rising investments in the research and development of various cell-based drugs and the increasing number of government investments in numerous countries for various clinical studies are anticipated to contribute to the growth of the market. Moreover, the growing developments in the biopharmaceutical & biotechnology industry in developing countries are further fueling the growth of the market over the forecast period.

The COVID-19 pandemic had a significant impact on the cell therapy raw materials industry. As the virus spread globally, disruptions in supply chains, workforce shortages, and transportation restrictions posed significant challenges to the production and distribution of critical raw materials required for cell therapy manufacturing. Many suppliers faced delays in the sourcing and delivery of essential components, such as growth factors, culture media, and bioreactors. This resulted in production slowdowns and increased costs for cell therapy companies. In addition, the heightened demand for medical supplies during the pandemic strained resources and led to price fluctuations. Despite these challenges, the cellular therapy industry demonstrated resilience by adapting to new sourcing strategies and regulatory changes, emphasizing the importance of supply chain diversification and preparedness in the face of unforeseen global crises.

Moreover, the cell therapy industry is anticipated to witness a significant surge in advancements and innovations by biopharma companies. These advances would be further propelled by the growing demand for effective cell-based therapies to treat a range of diseases and medical conditions. Furthermore, the growing expansion of various biotechnology and pharmaceutical companies is further expected to propel the growth of the market over the forecast period.

The increasing expansion of cellular therapy manufacturing along with rising FDA approvals are opening numerous opportunities for the raw materials market. Several manufacturers are opening such facilities to increase their footprint in the cellular therapy field. For instance, in June 2023, Bristol Myers Squibb received approval from the U.S. FDA to start its commercial production at its new cell therapy production facility in Devens, Massachusetts. For the long-term supply of the company's therapy portfolio, the Devens site is a crucial part of BMS' growing worldwide cell therapy production infrastructure.

However, the cost and affordability restrain the growth of the market. These materials, vital for cell therapy production, are costly to obtain and manufacture. This cost burden increases the expenses in the development and provision of cell-based therapies, potentially limiting their accessibility to a broader population due to financial constraints. Balancing quality and affordability is an acute concern in advancing cell therapies and ensuring their broader availability and acceptance within the healthcare industry.

 Request a free sample copy or view report summary: Cell Therapy Raw Materials Market Report

Cell Therapy Raw Materials Market Report Highlights

• The rapid progress made in biotherapeutics, and bioprocessing is significantly boosting the raw materials used in cell therapy production.

• The increasing global focus on treating complex and chronic diseases such as cancer, neurological disorders, autoimmune conditions, and rare genetic disorders has significantly intensified the demand for cell therapies.

• The degree of innovation in the cell therapy raw material industry is high, driven by rapidly advancing bioprocessing technologies and the evolving needs of next-generation therapies.

• The cell culture supplements segment held the largest market share of 25.18% in 2025. Due to the rising demand for animal-free cell-based therapies, the segment is anticipated to grow during the forecast period.

• The biopharmaceutical & pharmaceutical companies segment holds the largest share of 53.38% in 2025. These firms are acknowledging more and more revolutionary capability of cell therapies to cure cancer, autoimmune diseases

• North America cell therapy raw materials industry dominated the global market in 2025 with a share of 46.61%, driven by the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, which has increased demand for innovative cell-based therapies

Cell Therapy Raw Materials Market Segmentation

Grand View Research has segmented the global cell therapy raw materials market report based on product, end use, and region:

Cell Therapy Raw Materials  Product Outlook (Revenue, USD Million, 2021 - 2033)

• Media

• Sera

• Cell Culture Supplements

• Antibodies

• Reagents & Buffers

• Others

Cell Therapy Raw Materials  End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Others

Cell Therapy Raw Materials  Regional Outlook (Revenue, USD Million, 2021- 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Cell Therapy Raw Materials Market

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Danaher

• Sartorius Stedim Biotech

• Actylis.

• ACROBiosystems

• STEMCELL Technologies.

• Grifols, S.A.

• Charles River Laboratories

• RoosterBio, Inc.

• PromoCell GmbH